Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Imeglimin enhances insulin secretion in type 2 diabetes treatment
Last updated September 10, 2026
Key finding
HbA1c decreased by 0.75% at 24 weeks.
This study compared the effects of Imeglimin and Metformin on glycaemic control in patients with Type 2 Diabetes, finding that Imeglimin resulted in a significant decrease in HbA1c levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effects of Imeglimin and Metformin on glycaemic control in patients with Type 2 Diabetes, finding that Imeglimin resulted in a significant decrease in HbA1c levels.
Clinical relevance
These findings are significant as they suggest that Imeglimin may be a more effective option for managing blood sugar levels in patients with Type 2 Diabetes compared to Metformin. This could lead to better long-term health outcomes and improved management strategies for diabetes care.
Keep in mind
The study did not provide detailed demographic data on participants. Effectiveness of treatments beyond 24 weeks remains unclear. Sample size and generalizability to broader populations were not specified.
Published in
Journal Reference
Publication details and source links for this paper.
Ryota U, Yoshiyuki H, Masahiro I, et al. Comparative Effects of Imeglimin and Metformin on Glycaemic Control in Patients with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2024;27(2):856-865. doi:10.1111/dom.16086
Main Effects
HbA1c decreased by 0.75% at 24 weeks in the Imeglimin group.
Insulin levels increased only in the Imeglimin group.
HOMA-IR decreased in both Imeglimin and Metformin groups.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Imeglimin and Active GIP, Active GLP-1, Blood glucose, and 6 more.
This study contributes evidence to
Primary intervention
Imeglimin
Primary outcomes
- Active GIP
- Active GLP-1
- Blood glucose
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
9
Evidence pairs
9
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
9
Evidence pairs
1365
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 9 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Beta-Cell Function
matched_outcome
Related evidence
Evidence topic
Fasting Blood Glucose
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerHomeostatic Model Assessment of Beta-cell function (HOMA-β)
Imeglimin → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Imeglimin → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Imeglimin reduced HbA1c levels by 0.75% (p=0.05).
- Both treatments improved insulin resistance as indicated by HOMA-IR.
- Total GLP-1 levels increased in both treatment groups.
Who this applies to
- Adults diagnosed with Type 2 Diabetes.
- Patients currently on Metformin or considering alternative treatments.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- Long-term effects of Imeglimin were not evaluated.
- Further studies are needed to confirm these findings in larger cohorts.
Between the Lines
- The study did not provide detailed demographic data on participants.
- Effectiveness of treatments beyond 24 weeks remains unclear.
- Sample size and generalizability to broader populations were not specified.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Imeglimin and HbA1c, Imeglimin and Active GIP.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Imeglimin → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
Imeglimin → Active GIP
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
3 studies
outcome_hubMeasures HbA1c as a key outcome.
Imeglimin Evidence Hub
All studies on Imeglimin
3 studies
intervention_hubContributes to Imeglimin evidence base.
Active GIP Evidence Hub
All studies measuring Active GIP
1 studies
outcome_hubMeasures Active GIP as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Imeglimin and HbA1c
Intervention: ImegliminOutcome: HbA1c
3 results
All studies on Imeglimin and Active GIP
Intervention: ImegliminOutcome: Active GIP
1 results
All studies on Imeglimin
Intervention: Imeglimin
3 results
All studies measuring HbA1c
Outcome: HbA1c
3 results
All studies measuring Active GIP
Outcome: Active GIP
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Imeglimin lower HbA1c?
Strong Evidence
Imeglimin appears to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Imeglimin improve active gip?
Emerging Evidence
Imeglimin appears to improve active gip.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Active GIP
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Imeglimin improve active glp-1?
Emerging Evidence
Imeglimin appears to improve active glp-1.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Active GLP-1
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Imeglimin improve homeostatic model assessment of beta-cell function (homa-β)?
Emerging Evidence
Imeglimin appears to improve homeostatic model assessment of beta-cell function (homa-β).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Homeostatic Model Assessment of Beta-cell function (HOMA-β)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Imeglimin may prolong erythrocyte lifespan, affecting HbA1c levels.Natural products may improve glycemic control in type 2 diabetesBrown Seaweed Shows No Effect on Blood Glucose in DiabetesDietary fiber improves glycemic control in some prediabeticsHIIT Improves Glucose Control in Diabetic Neuropathy Patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.